Coronary Artery Disease
Target lesion failure with BRS? good old DES to the rescue
First published: 16 April 2016
Conflict of interest: Dr Michela Faggioni has no conflict of interest to disclose. Dr Roxana Mehran is a consultant for AstraZeneca, Bayer; CSL Behring; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Osprey Medical Inc.; Regado Biosciences, Inc.; The Medicines Company; Watermark Consulting; she has equity in Claret Medical Inc and Elixir Medical Corporation. She is part of the advisory board of Abbott Laboratories; AstraZeneca; Boston Scientific Corporation; Covidien; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; The Medicines Company; Sanofi-Aventis; she has received lecture honoraria from PlatformQ and Sanofi-Aventis
Key Points
- Target lesion revascularization (TLR) for BRS failure is burdened with a high rate of adverse events.
- DES implantation appears to be the safest treatment option following BRS failure.
- A real world observational study with a minimum of 2-year follow-up would be required to investigate the long-term clinical outcomes in patients with a BRS failure and to assess the best treatment option in case of TLR
